The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest

Trials Discussed:STAREE (NCT02099123)REACT (NCT06692127)AMUNDSEN (NCT04951856)ENRICH-AF (NCT03950076)LIBREXIA-ACS (NCT05754957)PREMIUM (NCT05709626)SWITCH SWEDEHEART (NCT05183178) EMAIL-HF (NCT05890131)ADHERE-ASCVD (NCT07522645)TIME-HF  (CTRI/2021/11/037797)H-HeFT & Met-HeFT  (DANHEART, NCT03514108)ACASA-TAVI (NCT05035277)

CARDIO-TTRansform — eplontersen in transthyretin amyloid cardiomyopathy (ATTR-CM). ClinicalTrials.gov: NCT04136171SINGLE-AF — direct oral anticoagulation in patients with atrial fibrillation at intermediate stroke risk. ClinicalTrials.gov: NCT04437654POET II — response-tailored, shortened antibiotic therapy in left-sided infective endocarditis. ClinicalTrials.gov: NCT03851575

Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee

Learn more about the AHA scientific statement here. 

In this episode of The Tell-Tale Heart, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, welcomes back Lavinia Salama, PharmD, BCACP, BCGP, BC-ADM, CDCES, for an in-depth look at the new cardiovascular-kidney-metabolic (CKM) guidelines and how they translate into everyday practice. Salama says she's encouraged that CKM recommendations have evolved from a conceptual framework into a formal, multisociety guideline, with new emphasis on albuminuria, the PREVENT risk equation, and routine screening for obstructive sleep apnea, MASLD/MASH, and social determinants of health.